Structure via PubChem · Public domain (PubChem)
cerlapirdine
Sign in to saveAlso known as PF-05212365, SAM-531, WAY-262531
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.
In the Vinony graph
Vinony's link graph records 1,366 inbound references to cerlapirdine, and connects out to N-methylserotonin, glaucine and azasetron.
Vinony files it under 1-Naphthyl compounds, Abandoned drugs and Chemical pages without DrugBank identifier.
Vinony links it to 5 Wikipedia language editions.
Chemical data
- Formula
- C22H23N3O3S
- Molecular weight
- 409.5 g/mol
- IUPAC name
- N,N-dimethyl-3-[(3-naphthalen-1-ylsulfonyl-2H-indazol-5-yl)oxy]propan-1-amine
- SMILES
- CN(C)CCCOC1=CC2=C(NN=C2C=C1)S(=O)(=O)C3=CC=CC4=CC=CC=C43
- InChIKey
- NXQGEDVQXVTCDA-UHFFFAOYSA-N
- XLogP
- 4.3
- Polar surface area
- 83.7 Ų
- H-bond donors
- 1
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- Alzheimer disease
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 409.146013
Show 3 more facts
- chemical formula
- C₂₂H₂₃N₃O₃S
- canonical SMILES
- CN(C)CCCOC1=CC2=C(NN=C2C=C1)S(=O)(=O)C3=CC=CC4=CC=CC=C43
- Commons category
- Cerlapirdine
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Cerlapirdine (USAN; SAM-531, WAY-262,531, PF-05212365) is a drug which was under development by Wyeth/Pfizer for the treatment of cognitive disorders associated with Alzheimer's disease and schizophrenia. In a phase II clinical trial it demonstrated a trend toward efficacy along with a good side effect profile and no incidence of serious adverse events, but no further development has occurred since 2011.
It exerts its effects by acting as a selective 5-HT6 receptor antagonist.
Excerpted from Wikipedia’s “cerlapirdine” article, available under the CC BY-SA 4.0 licence.